UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (182) 182
life sciences & biomedicine (174) 174
oncology (159) 159
humans (154) 154
lung neoplasms - drug therapy (91) 91
female (90) 90
carcinoma, non-small-cell lung - drug therapy (82) 82
male (77) 77
middle aged (77) 77
aged (76) 76
lung cancer (65) 65
lung neoplasms - pathology (59) 59
adult (58) 58
lung neoplasms - genetics (49) 49
carcinoma, non-small-cell lung - genetics (46) 46
lung cancer, non-small cell (45) 45
respiratory system (44) 44
antineoplastic combined chemotherapy protocols - therapeutic use (42) 42
chemotherapy (42) 42
carcinoma, non-small-cell lung - pathology (41) 41
treatment outcome (40) 40
cancer (36) 36
mutation (36) 36
antineoplastic agents - therapeutic use (34) 34
neoplasm staging (33) 33
aged, 80 and over (30) 30
nsclc (29) 29
lung neoplasms - mortality (28) 28
tumors (26) 26
care and treatment (25) 25
disease-free survival (25) 25
hematology, oncology and palliative medicine (23) 23
lung neoplasms - therapy (23) 23
non-small cell lung carcinoma (23) 23
patients (23) 23
carcinoma, non-small-cell lung - mortality (22) 22
metastasis (22) 22
survival analysis (21) 21
prognosis (20) 20
cancer therapies (18) 18
cisplatin - administration & dosage (18) 18
general & internal medicine (18) 18
lung neoplasms - diagnosis (18) 18
protein kinase inhibitors - therapeutic use (18) 18
carcinoma, non-small-cell lung - therapy (17) 17
kaplan-meier estimate (17) 17
non-small cell lung cancer (17) 17
pulmonary/respiratory (17) 17
abridged index medicus (16) 16
antineoplastic combined chemotherapy protocols - adverse effects (16) 16
biomarkers (15) 15
carcinoma, non-small-cell lung - diagnosis (15) 15
non-small-cell lung cancer (15) 15
pulmonary and respiratory medicine (15) 15
analysis (14) 14
antineoplastic agents - adverse effects (14) 14
carboplatin - administration & dosage (14) 14
drug administration schedule (14) 14
epidermal growth factor receptors (14) 14
quinazolines - therapeutic use (14) 14
animals (13) 13
clinical trials (13) 13
egfr (13) 13
erlotinib (13) 13
immunotherapy (13) 13
medicine & public health (13) 13
medicine, general & internal (13) 13
respiratory tract diseases (13) 13
610 medicine & health (12) 12
clinical trials as topic (12) 12
disease progression (12) 12
protein kinase inhibitors - adverse effects (12) 12
protein-tyrosine kinase (12) 12
survival rate (12) 12
tyrosine (12) 12
antibodies, monoclonal - therapeutic use (11) 11
apoptosis (11) 11
epidermal growth factor (11) 11
erlotinib hydrochloride (11) 11
europe (11) 11
lung neoplasms - enzymology (11) 11
metastases (11) 11
pd-l1 protein (11) 11
receptor, epidermal growth factor - antagonists & inhibitors (11) 11
research (11) 11
small cell lung carcinoma (11) 11
survival (11) 11
adenocarcinoma (10) 10
alk (10) 10
carcinoma, non-small-cell lung - enzymology (10) 10
combined modality therapy (10) 10
erbb receptors - genetics (10) 10
gene expression (10) 10
lung neoplasms - metabolism (10) 10
lung neoplasms - surgery (10) 10
quality of life (10) 10
receptor protein-tyrosine kinases - genetics (10) 10
receptor, epidermal growth factor - genetics (10) 10
antibodies, monoclonal, humanized - therapeutic use (9) 9
biomarkers, tumor - genetics (9) 9
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
The New England journal of medicine, ISSN 1533-4406, 05/2018, Volume 378, Issue 22, pp. 2078 - 2092
The addition of pembrolizumab to chemotherapy for metastatic lung cancer without EGFR or ALK mutations resulted in better progression-free and overall survival... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Carcinoma, Non-Small-Cell Lung - secondary | Aged, 80 and over | Adult | Female | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Double-Blind Method | Carcinoma, Non-Small-Cell Lung - genetics | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Antineoplastic Agents, Immunological - adverse effects | Antineoplastic Agents, Immunological - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Treatment outcome | Care and treatment | Chemotherapy | Usage | Analysis | Lung cancer, Non-small cell | Drug therapy | Cancer | Epidermal growth factor receptors | Laboratories | Lung cancer | Non-small cell lung carcinoma | Cytotoxicity | Metastasis | Patients | Cancer therapies | Metastases | Pembrolizumab | Hospitals | Platinum | PD-L1 protein | Response rates | Death | Mutation | Apoptosis | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 04/2016, Volume 387, Issue 10027, pp. 1540 - 1550
Summary Background Despite recent advances in the treatment of advanced non-small-cell lung cancer, there remains a need for effective treatments for... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Gene Expression Regulation, Neoplastic | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Antineoplastic Agents - administration & dosage | Molecular Targeted Therapy | Patient Selection | Taxoids - therapeutic use | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Agents - adverse effects | Adult | Female | Taxoids - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Antibodies, Monoclonal, Humanized - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Drug Administration Schedule | Lung Neoplasms - chemistry | Docetaxel | Kaplan-Meier Estimate | Treatment Outcome | Disease-Free Survival | Taxoids - administration & dosage | Aged | B7-H1 Antigen - analysis | Carcinoma, Non-Small-Cell Lung - drug therapy | Antimitotic agents | Medical colleges | Lung cancer, Non-small cell | Antineoplastic agents | Analysis | Chemotherapy | Biopsy | Genes | Lung cancer | Clinical trials | Oncology | Mutation | Tumors | Cell survival | Medical treatment | FDA approval | Health care facilities | Survival | Patients | Evidence-based medicine | Pembrolizumab | Randomization | Interactive systems | Immunotherapy | Risk assessment | PD-L1 protein | Biomarkers | Index Medicus | Abridged Index Medicus
Journal Article
The lancet oncology, ISSN 1470-2045, 02/2016, Volume 17, Issue 2, pp. 212 - 223
Summary Background MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia... 
Hematology, Oncology and Palliative Medicine | Life Sciences & Biomedicine | Oncology | Science & Technology | Predictive Value of Tests | Carcinoma, Non-Small-Cell Lung - chemistry | Humans | Middle Aged | Fatigue - etiology | Male | Cisplatin - administration & dosage | Antigens, CD - analysis | Antigens, Differentiation, T-Lymphocyte - analysis | Neutropenia - etiology | Cancer Vaccines - therapeutic use | Receptors, IgG - analysis | Mucin-1 - analysis | Lectins, C-Type - analysis | Female | Paclitaxel - administration & dosage | Lymphocytes - chemistry | Anemia - etiology | Bevacizumab - administration & dosage | Double-Blind Method | Lung Neoplasms - chemistry | Lymphocyte Activation | CD56 Antigen - analysis | Deoxycytidine - administration & dosage | Erlotinib Hydrochloride - administration & dosage | Carboplatin - administration & dosage | Cancer Vaccines - adverse effects | Lung Neoplasms - therapy | Immunotherapy - adverse effects | Biomarkers, Tumor - blood | Disease-Free Survival | Carcinoma, Non-Small-Cell Lung - therapy | Membrane Glycoproteins - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Pemetrexed - administration & dosage | Aged | Membrane Glycoproteins - adverse effects | Deoxycytidine - analogs & derivatives | Antigens | Fc receptors | Hospitals | Interleukins | Immunotherapy | Mucins | Clinical trials | Product development | Lung cancer, Non-small cell | Analysis | Index Medicus
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
Cancer research (Chicago, Ill.), ISSN 1538-7445, 07/2017, Volume 77, Issue 13, pp. 3540 - 3550
Antibody targeting of the immune checkpoint receptor PD1 produces therapeutic activity in a variety of solid tumors, but most patients exhibit partial or... 
Life Sciences & Biomedicine | Oncology | Science & Technology | Gene Expression - drug effects | Carcinoma, Squamous Cell - genetics | Carcinoma, Squamous Cell - pathology | Humans | Middle Aged | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Squamous Cell Carcinoma of Head and Neck | Melanoma - genetics | Gene Expression - immunology | Aged, 80 and over | Adult | Female | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - genetics | Antibodies, Monoclonal, Humanized - therapeutic use | Carcinoma, Non-Small-Cell Lung - genetics | Head and Neck Neoplasms - drug therapy | Gene Expression Profiling - methods | Melanoma - pathology | Head and Neck Neoplasms - pathology | Carcinoma, Non-Small-Cell Lung - immunology | Lung Neoplasms - immunology | Carcinoma, Squamous Cell - drug therapy | Melanoma - immunology | Melanoma - drug therapy | Nivolumab | Head and Neck Neoplasms - genetics | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Programmed Cell Death 1 Receptor - immunology | Programmed Cell Death 1 Receptor - genetics | PD-1 protein | CD8 antigen | Antibodies | Lymphocytes T | Killer cells | Cell activation | Lymphocytes | Natural killer cells | Signatures | Immune system | Squamous cell carcinoma | Head | Immune response | Small cell lung carcinoma | Tumor-infiltrating lymphocytes | Melanoma | Lung carcinoma | Gene expression | Ribonucleic acid--RNA | Patients | CD4 antigen | Immune checkpoint | Reproducibility | PD-L1 protein | Biomarkers | Head and neck cancer | Interferon | Solid tumors | Cancer | Tumors | Index Medicus
Journal Article
Nature communications, ISSN 2041-1723, 11/2015, Volume 6, Issue 1, pp. 8839 - 8839
Journal Article
The lancet oncology, ISSN 1470-2045, 07/2017, Volume 18, Issue 7, pp. 874 - 886
Journal Article